RT Journal Article
T1 Exofucosylation of adipose mesenchymal stromal cells alters their secretome profile
A1 García-Bernal, David
A1 García-Arranz, Mariano
A1 García-Guillén, Ana I.
A1 García-Hernández, Ana M.
A1 Blanquer, Miguel
A1 García-Olmo, Damián
A1 Sackstein, Robert
A1 Moraleda, José María
A1 Zapata González, Agustín
AB Mesenchymal stromal cells (MSCs) constitute the cell type more frequently used in many regenerative medicine approaches due to their exclusive immunomodulatory properties, and they have been reported to mediate profound immunomodulatory effects in vivo. Nevertheless, MSCs do not express essential adhesion molecules actively involved in cell migration, a phenotypic feature that hampers their ability to home inflamed tissues following intravenous administration. In this study, we investigated whether modification by fucosylation of murine AdMSCs (mAdMSCs) creates Hematopoietic Cell E-/L-selectin Ligand, the E-selectin-binding CD44 glycoform. This cell surface glycan modification of CD44 has previously shown in preclinical studies to favor trafficking of mAdMSCs to inflamed or injured peripheral tissues. We analyzed the impact that exofucosylation could have in other innate phenotypic and functional properties of MSCs. Compared to unmodified counterparts, fucosylated mAdMSCs demonstrated higher in vitro migration, an altered secretome pattern, including increased expression and secretion of anti-inflammatory molecules, and a higher capacity to inhibit mitogenstimulated splenocyte proliferation under standard culture conditions. Together, these findings indicate that exofucosylation could represent a suitable cell engineering strategy, not only to facilitate the in vivo MSC colonization of damaged tissues after systemic administration, but also to convert MSCs in a more potent immunomodulatory/antiinflammatory cell therapy-based product for the treatment of a variety of autoimmune, inflammatory, and degenerative diseases.
PB Frontiers Media
SN 2296-634X
YR 2020
FD 2020-11-26
LK https://hdl.handle.net/20.500.14352/8069
UL https://hdl.handle.net/20.500.14352/8069
LA eng
NO Plan Estatal Español de Investigación Científica y Técnica y de Innovación 2013–2016. RETICS
NO Instituto de Salud Carlos III (ISCIII)/Fondo Europeo de Desarrollo Regional(FEDER)
DS Docta Complutense
RD 7 abr 2025